MA27665A1 - Triazoles substitues diaryle comme bloqueurs des canaux sodiques - Google Patents
Triazoles substitues diaryle comme bloqueurs des canaux sodiquesInfo
- Publication number
- MA27665A1 MA27665A1 MA28481A MA28481A MA27665A1 MA 27665 A1 MA27665 A1 MA 27665A1 MA 28481 A MA28481 A MA 28481A MA 28481 A MA28481 A MA 28481A MA 27665 A1 MA27665 A1 MA 27665A1
- Authority
- MA
- Morocco
- Prior art keywords
- compounds
- pain
- relates
- alone
- pharmaceutically acceptable
- Prior art date
Links
- YCWSUKQGVSGXJO-NTUHNPAUSA-N nifuroxazide Chemical group C1=CC(O)=CC=C1C(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 YCWSUKQGVSGXJO-NTUHNPAUSA-N 0.000 title 1
- 239000003195 sodium channel blocking agent Substances 0.000 title 1
- 150000003852 triazoles Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 7
- 238000000034 method Methods 0.000 abstract 3
- 208000002193 Pain Diseases 0.000 abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000000094 Chronic Pain Diseases 0.000 abstract 1
- 206010065390 Inflammatory pain Diseases 0.000 abstract 1
- 108010052164 Sodium Channels Proteins 0.000 abstract 1
- 102000018674 Sodium Channels Human genes 0.000 abstract 1
- 208000005298 acute pain Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 1
- 238000002690 local anesthesia Methods 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 208000021722 neuropathic pain Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- -1 triazole compounds Chemical class 0.000 abstract 1
- 208000009935 visceral pain Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne des composés triazole substitués par du biaryle, représentés par la formule (I), (II) ou (III), ou des sels acceptables sur le plan pharmaceutique de ceux-ci. L'invention concerne également un procédé de préparation de tels composés et des sels de ceux-ci, ainsi que des compositions pharmaceutiques renfermant une quantité efficace des composés selon l'invention, soit seuls, soit avec un ou plusieurs autres composés actifs sur le plan thérapeutique, et un excipient acceptable sur le plan pharmaceutique. L'invention concerne, en outre, des méthodes de traitement d'états associés à l'activité des canaux sodiques ou engendrés par celle-ci, notamment, par exemple, des douleurs aigues, des douleurs chroniques, des douleurs viscérales, des douleurs inflammatoires, des douleurs neuropathiques, l'épilepsie, le syndrome du côlon irritable, la dépression, l'anxiété, la sclérose en plaques et un trouble polaire, consistant à administrer une quantité efficace des composés selon l'invention, soit seuls, soit conjointement avec un ou plusieurs autres composés actifs sur le plan thérapeutique. L'invention concerne enfin un procédé d'anesthésie locale consistant à administrer une quantité efficace d'un composé selon l'invention, soit seul, soit conjointement avec un ou plusieurs composés actifs sur le plan thérapeutique, et un excipient acceptable sur le plan pharmaceutique.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45595203P | 2003-03-18 | 2003-03-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA27665A1 true MA27665A1 (fr) | 2005-12-01 |
Family
ID=33030073
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA28481A MA27665A1 (fr) | 2003-03-18 | 2005-09-06 | Triazoles substitues diaryle comme bloqueurs des canaux sodiques |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US7326726B2 (fr) |
| EP (1) | EP1606269B1 (fr) |
| JP (1) | JP4482554B2 (fr) |
| KR (1) | KR100737721B1 (fr) |
| CN (2) | CN1788002A (fr) |
| AR (1) | AR044503A1 (fr) |
| AT (1) | ATE412639T1 (fr) |
| AU (1) | AU2004221885C1 (fr) |
| BR (1) | BRPI0408407A (fr) |
| CA (1) | CA2519252C (fr) |
| CL (1) | CL2004000551A1 (fr) |
| CY (1) | CY1108720T1 (fr) |
| DE (1) | DE602004017438D1 (fr) |
| DK (1) | DK1606269T3 (fr) |
| EC (1) | ECSP056018A (fr) |
| EG (1) | EG25994A (fr) |
| ES (1) | ES2314387T3 (fr) |
| HR (1) | HRP20050816A2 (fr) |
| IS (1) | IS8001A (fr) |
| JO (1) | JO2480B1 (fr) |
| MA (1) | MA27665A1 (fr) |
| MX (1) | MXPA05009847A (fr) |
| MY (1) | MY142651A (fr) |
| NO (1) | NO20054775L (fr) |
| NZ (1) | NZ542205A (fr) |
| PE (1) | PE20041066A1 (fr) |
| PL (1) | PL1606269T3 (fr) |
| PT (1) | PT1606269E (fr) |
| RU (1) | RU2356897C2 (fr) |
| SI (1) | SI1606269T1 (fr) |
| TW (1) | TWI337605B (fr) |
| UA (1) | UA81660C2 (fr) |
| WO (2) | WO2004083190A1 (fr) |
| ZA (1) | ZA200506906B (fr) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE405840T1 (de) | 2002-12-19 | 2008-09-15 | Scripps Research Inst | Zusammensetzungen und verfahren zur stabilisierung von transthyretin und zur hemmung von transthyretin-fehlfaltung |
| MY142651A (en) * | 2003-03-18 | 2010-12-15 | Merck Sharp & Dohme | Biaryl substituted triazoles as sodium channel blockers |
| ATE500234T1 (de) * | 2003-11-10 | 2011-03-15 | Merck Sharp & Dohme | Substituierte trialzole als blocker des natriumkanals |
| KR20070032700A (ko) | 2004-05-20 | 2007-03-22 | 폴드알엑스 파마슈티칼스, 인크. | 트랜스티레틴을 안정화하고 트랜스티레틴 미스폴딩을억제하기 위한, ２-((헤테로)아릴)-벤즈옥사졸 화합물 및유도체, 그리고 조성물 및 방법 |
| ATE472529T1 (de) | 2005-10-10 | 2010-07-15 | Glaxo Group Ltd | Prolinamidderivate als natriumkanalmodulatoren |
| TW200728258A (en) | 2005-10-10 | 2007-08-01 | Glaxo Group Ltd | Novel compounds |
| TW200730494A (en) | 2005-10-10 | 2007-08-16 | Glaxo Group Ltd | Novel compounds |
| WO2008090114A1 (fr) | 2007-01-24 | 2008-07-31 | Glaxo Group Limited | Compositions pharmaceutiques contenant du 2-méthoxy-5- (5-trifluorométhyl-tétrazol-i-yl-benzyl) - (2s-phényl-pipéridin-3s-yl-) |
| US8299107B2 (en) * | 2007-02-08 | 2012-10-30 | Synta Pharmaceuticals Corporation | Triazole compounds that modulate HSP90 activity |
| EP2520561B1 (fr) | 2007-06-08 | 2016-02-10 | MannKind Corporation | Inhibiteurs IRE-1A |
| US8952034B2 (en) | 2009-07-27 | 2015-02-10 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
| BR112012033402A2 (pt) | 2010-07-02 | 2017-01-24 | Gilead Sciences Inc | moduladores de canais de íons conforme os compostos heterocíclicos fundidos |
| CA2834164A1 (fr) | 2011-05-10 | 2012-11-15 | Gilead Sciences, Inc. | Benzoxazinones fusionnees comme modulateurs de canal ionique |
| TW201837023A (zh) | 2011-07-01 | 2018-10-16 | 美商基利科學股份有限公司 | 作為離子通道調節劑之稠合雜環化合物 |
| NO3175985T3 (fr) | 2011-07-01 | 2018-04-28 | ||
| RU2586330C2 (ru) | 2011-09-16 | 2016-06-10 | Пфайзер Инк. | Твердые формы ингибитора диссоциации транстиретина |
| WO2013131018A1 (fr) * | 2012-03-02 | 2013-09-06 | Zalicus Pharmaceuticals Ltd. | Inhibiteurs biaryle du canal sodique |
| TWI568722B (zh) | 2012-06-15 | 2017-02-01 | 葛蘭馬克製藥公司 | 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物 |
| JP6456909B2 (ja) | 2013-03-15 | 2019-01-23 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｌｘｒ調節因子 |
| ES2912881T3 (es) | 2014-12-23 | 2022-05-30 | Convergence Pharmaceuticals | Procedimiento para preparar derivados de alfa-carboxamida pirrolidina |
| JP6616244B2 (ja) * | 2015-05-29 | 2019-12-04 | 北興化学工業株式会社 | 新規なヒドロキシフェニルボロン酸エステルとその製造方法、およびヒドロキシビフェニル化合物の製造法 |
| CA3076823A1 (fr) | 2017-10-05 | 2019-04-11 | Biogen Inc. | Procede de preparation de derives d'alpha-carboxamide de pyrrolidine |
| KR102512548B1 (ko) | 2017-12-22 | 2023-03-22 | 삼성디스플레이 주식회사 | 유기 전계 발광 소자 및 유기 전계 발광 소자용 함질소 화합물 |
| US20210002232A1 (en) * | 2018-03-09 | 2021-01-07 | Pi Industries Ltd. | Heterocyclic compounds as fungicides |
| CN108863965A (zh) * | 2018-06-25 | 2018-11-23 | 青岛科技大学 | 一锅法制备1,2,4-三氮唑-3-甲酰胺的方法 |
| CN108794413A (zh) * | 2018-06-25 | 2018-11-13 | 青岛科技大学 | 一种1,2,4-三氮唑-3-甲酰胺的合成方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US875782A (en) * | 1907-04-29 | 1908-01-07 | Walter H Cook | Fast-nut. |
| TW226993B (fr) * | 1992-05-29 | 1994-07-21 | Kumiai Chemical Industry Co | |
| US5455252A (en) * | 1993-03-31 | 1995-10-03 | Syntex (U.S.A.) Inc. | Optionally substituted 6,8-quinolines |
| JP3682075B2 (ja) * | 1993-04-16 | 2005-08-10 | クミアイ化学工業株式会社 | トリアゾール誘導体及び殺虫、殺ダニ剤 |
| TW533205B (en) * | 1996-06-25 | 2003-05-21 | Novartis Ag | Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition |
| IT1292091B1 (it) * | 1997-06-05 | 1999-01-25 | Geange Ltd | Derivati eterociclici aromatici azotati,procedimento per la loro preparazione e loro impiego come antigestativi,immunosoppressori e |
| GB9726987D0 (en) | 1997-12-22 | 1998-02-18 | Glaxo Group Ltd | Compounds |
| CA2368631A1 (fr) | 1999-03-26 | 2000-10-05 | Euro-Celtique S.A. | Pyrazoles, imidazoles, oxazoles, thiazoles et pyrroles aryle substitues et leurs utilisations |
| AR029489A1 (es) | 2000-03-10 | 2003-07-02 | Euro Celtique Sa | Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento |
| JP2004532234A (ja) * | 2001-04-27 | 2004-10-21 | バーテックス ファーマシューティカルズ インコーポレイテッド | トリアゾール由来キナーゼインヒビターおよびその使用 |
| US6797722B2 (en) * | 2002-05-03 | 2004-09-28 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Use of 3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1H-1,2,4-triazole for the treatment of autoimmune diseases |
| BR0312503A (pt) * | 2002-07-09 | 2007-06-26 | Bristol Myers Squibb Co | derivados heterocìclicos substituìdos úteis como agentes antidiabéticos e antiobesidade, composição farmacêutica, uso e combinação dos mesmos |
| KR100467668B1 (ko) * | 2002-08-07 | 2005-01-24 | 씨제이 주식회사 | 1,2,4-트리아졸 유도체, 그 제조방법 및 약제학적 조성물 |
| KR100470075B1 (ko) * | 2002-11-21 | 2005-02-05 | 씨제이 주식회사 | 1,2,4-트리아졸 유도체, 그 제조방법 및 약제학적 조성물 |
| JO2397B1 (en) * | 2002-12-20 | 2007-06-17 | ميرك شارب اند دوم كوربوريشن | Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors |
| MY142651A (en) * | 2003-03-18 | 2010-12-15 | Merck Sharp & Dohme | Biaryl substituted triazoles as sodium channel blockers |
| ATE500234T1 (de) * | 2003-11-10 | 2011-03-15 | Merck Sharp & Dohme | Substituierte trialzole als blocker des natriumkanals |
-
2004
- 2004-03-11 MY MYPI20040842A patent/MY142651A/en unknown
- 2004-03-11 AR ARP040100789A patent/AR044503A1/es unknown
- 2004-03-12 ES ES04720360T patent/ES2314387T3/es not_active Expired - Lifetime
- 2004-03-12 CN CNA200480013089XA patent/CN1788002A/zh active Pending
- 2004-03-12 AT AT04720360T patent/ATE412639T1/de active
- 2004-03-12 SI SI200430959T patent/SI1606269T1/sl unknown
- 2004-03-12 NZ NZ542205A patent/NZ542205A/en not_active IP Right Cessation
- 2004-03-12 CN CNA2008101000997A patent/CN101289428A/zh active Pending
- 2004-03-12 DE DE602004017438T patent/DE602004017438D1/de not_active Expired - Lifetime
- 2004-03-12 HR HR20050816A patent/HRP20050816A2/hr not_active Application Discontinuation
- 2004-03-12 BR BRPI0408407-1A patent/BRPI0408407A/pt not_active IP Right Cessation
- 2004-03-12 EP EP04720360A patent/EP1606269B1/fr not_active Expired - Lifetime
- 2004-03-12 AU AU2004221885A patent/AU2004221885C1/en not_active Ceased
- 2004-03-12 DK DK04720360T patent/DK1606269T3/da active
- 2004-03-12 WO PCT/US2004/007830 patent/WO2004083190A1/fr not_active Ceased
- 2004-03-12 US US10/799,230 patent/US7326726B2/en not_active Expired - Lifetime
- 2004-03-12 CA CA002519252A patent/CA2519252C/fr not_active Expired - Fee Related
- 2004-03-12 PL PL04720360T patent/PL1606269T3/pl unknown
- 2004-03-12 UA UAA200509759A patent/UA81660C2/ru unknown
- 2004-03-12 KR KR1020057017327A patent/KR100737721B1/ko not_active Expired - Fee Related
- 2004-03-12 RU RU2005132168/04A patent/RU2356897C2/ru not_active IP Right Cessation
- 2004-03-12 MX MXPA05009847A patent/MXPA05009847A/es active IP Right Grant
- 2004-03-12 JP JP2006507122A patent/JP4482554B2/ja not_active Expired - Fee Related
- 2004-03-12 WO PCT/US2004/007597 patent/WO2004083189A1/fr not_active Ceased
- 2004-03-12 PT PT04720360T patent/PT1606269E/pt unknown
- 2004-03-14 JO JO200430A patent/JO2480B1/en active
- 2004-03-16 PE PE2004000280A patent/PE20041066A1/es not_active Application Discontinuation
- 2004-03-17 TW TW093107083A patent/TWI337605B/zh not_active IP Right Cessation
- 2004-03-17 CL CL200400551A patent/CL2004000551A1/es unknown
-
2005
- 2005-08-29 IS IS8001A patent/IS8001A/is unknown
- 2005-08-29 ZA ZA200506906A patent/ZA200506906B/xx unknown
- 2005-09-06 MA MA28481A patent/MA27665A1/fr unknown
- 2005-09-14 EC EC2005006018A patent/ECSP056018A/es unknown
- 2005-09-18 EG EGNA2005000548 patent/EG25994A/xx active
- 2005-10-17 NO NO20054775A patent/NO20054775L/no not_active Application Discontinuation
-
2008
- 2008-01-30 US US12/011,967 patent/US7572822B2/en not_active Expired - Lifetime
-
2009
- 2009-01-15 CY CY20091100054T patent/CY1108720T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA27665A1 (fr) | Triazoles substitues diaryle comme bloqueurs des canaux sodiques | |
| RU2203274C2 (ru) | Спироциклические ингибиторы металлопротеаз | |
| TN2009000544A1 (fr) | Derives de benzimidazole | |
| TNSN08270A1 (fr) | Dérivés pyrimidiques destinés à traiter une croissance cellulaire anormale | |
| TN2009000138A1 (fr) | Biaryl-ether-urees | |
| ATE196762T1 (de) | Arylsulfonamido-substituierte hydroxamsäure derivate als matrix-metalloproteinase inhibitoren | |
| MA33720B1 (fr) | Inhibiteurs peptiques cycliques de la replication du virus de l'hépatite c | |
| MA31497B1 (fr) | Nouveaux inhibiteurs peptidiques de la replication du virus de l'hepatite c | |
| WO2001081312A3 (fr) | Methode de traitement se basant sur l'utilisation de derives de phenyle et de biaryle comme inhibiteurs de prostaglandine e | |
| MA27957A1 (fr) | Agents derivatifs de quinolinone comme inhibiteurs de tyrosine kinase | |
| MA31319B1 (fr) | Dérivés de sulfonylamides destines au traitement d'une croissance cellulaire anormale | |
| MA27937A1 (fr) | Dérivés d'indazole 3, 5-disubstitués, compositions pharmaceutiques, et méthodes de médiation ou d'inhibition de la prolifération cellulaire | |
| MA29566B1 (fr) | Composes chimiques | |
| MA27781A1 (fr) | 3-fluoro-piperidines comme antagonistes de nmda/nr2b. | |
| CA2433039A1 (fr) | Agent pour le traitement prophylactique et therapeutique de la douleur neuropathique | |
| IL175522A0 (en) | Substituted triazoles as sodium channel blockers | |
| MA27762A1 (fr) | Utilisation de derives de 10-hydroxy-10, 11-dihydrocarbamazepine pour le traitement de troubles affectifs | |
| FR2521134A1 (fr) | Urees et thio-urees substituees, leur procede de preparation et leur application therapeutique comme medicaments anti-atherosclereux | |
| MA27716A1 (fr) | 4-aminopyrimidine-5-one | |
| MA68743B1 (fr) | Composés et compositions pour le traitement d'états associés à l'activité du récepteur de lpa | |
| FR2405067A1 (fr) | Compositions pharmaceutiques contenant des derives monofonctionnels du psoralene pour le traitement des affections cutanees | |
| EA200400523A1 (ru) | Производные [[2-(амино-3,4-диоксо-1-циклобутен-1-ил)амино]алкил] кислоты, применяемые для лечения боли | |
| MA61866B1 (fr) | Préparation de dérivés de benzimidazolone servant de nouveaux inhibiteurs de diacylglycéride o-acyltransférase 2 | |
| KR960703845A (ko) | 페녹시페닐 사이클로펜테닐 하이드록시우레아(phenoxyphenyl cyclopentenyl hydroxyureas) | |
| WO1998057925A1 (fr) | Augmentation du taux de cholesterol hdl par 2-[(aminothioxomethyl)hydrazono]-2-arylethyle carbamates |